The slower pace of getting genetherapies to patients will most likely require the development ofnew standards and means of production. (Photo: Getty)

Despite the enormous promise of gene therapies, challenges in producing thosetherapies may put them out of reach of most American consumers atleast in the near future, a new report said.

The report by the PWC Health Research Institute (HRI), outlines amyriad of challenges for gene therapies. Such therapies often aremodified for single patients, raising questions of the scalabilityof the treatments. Rapid production is difficult—but patients areoften facing life-threatening diseases and may not have much time.Supply chains and availability are limited: the report notes thatonly five ZIP codes in the country have health systems that offerall four gene therapies that currently have FDA approval.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.